Achillion Pharmaceuticals Inc (ACHN)

4.06
NASDAQ : Health Care
Prev Close 3.97
Day Low/High 3.91 / 4.12
52 Wk Low/High 3.78 / 10.95
Avg Volume 2.19M
Exchange NASDAQ
Shares Outstanding 136.68M
Market Cap 542.62M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Achillion Pharmaceuticals Becomes Oversold (ACHN)

Achillion Pharmaceuticals Becomes Oversold (ACHN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of ACHN June 2017 Options Trading

First Week of ACHN June 2017 Options Trading

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading this week, for the June 2017 expiration.

Interesting ACHN Put And Call Options For November 18th

Interesting ACHN Put And Call Options For November 18th

Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the November 18th expiration.

Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference

Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference

ePoster presentation to detail study results including SVR12 for eight and six week triplet regimen and eight week doublet regimen

ACHN August 26th Options Begin Trading

ACHN August 26th Options Begin Trading

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 26th expiration.

Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades

Achillion Pharmaceuticals (ACHN) Stock Up, JMP Upgrades

Achillion Pharmaceuticals (ACHN) stock rating was increased this morning to 'market outperform' at JMP as the firm believes the company's factor D program is a 'game changer.'

Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More

Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More

Here are Thursday's top research calls, including an upgrade for Zions, and downgrades for First Solar, Qualcomm and Red Hat.

Interesting ACHN Put And Call Options For August 5th

Interesting ACHN Put And Call Options For August 5th

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the August 5th expiration.

Achillion Pharmaceuticals (ACHN) Weak On High Volume Today

Achillion Pharmaceuticals (ACHN) Weak On High Volume Today

Trade-Ideas LLC identified Achillion Pharmaceuticals (ACHN) as a weak on high relative volume candidate

Achillion Reports 2015 Fourth Quarter And Year-End Financial Results

Achillion Reports 2015 Fourth Quarter And Year-End Financial Results

Strong Balance Sheet to Support Planned 2016 Clinical Expansion of Complement Factor D Platform

Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases